AR088369A1 - Sistema de administracion de farmaco de dos fases - Google Patents

Sistema de administracion de farmaco de dos fases

Info

Publication number
AR088369A1
AR088369A1 ARP120103874A ARP120103874A AR088369A1 AR 088369 A1 AR088369 A1 AR 088369A1 AR P120103874 A ARP120103874 A AR P120103874A AR P120103874 A ARP120103874 A AR P120103874A AR 088369 A1 AR088369 A1 AR 088369A1
Authority
AR
Argentina
Prior art keywords
hydrogel
particles
active ingredient
phase
administration system
Prior art date
Application number
ARP120103874A
Other languages
English (en)
Spanish (es)
Inventor
Jrgen Maier Hans
Original Assignee
Rp Scherer Technologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rp Scherer Technologies Llc filed Critical Rp Scherer Technologies Llc
Publication of AR088369A1 publication Critical patent/AR088369A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP120103874A 2011-10-19 2012-10-18 Sistema de administracion de farmaco de dos fases AR088369A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161548837P 2011-10-19 2011-10-19

Publications (1)

Publication Number Publication Date
AR088369A1 true AR088369A1 (es) 2014-05-28

Family

ID=48135086

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120103874A AR088369A1 (es) 2011-10-19 2012-10-18 Sistema de administracion de farmaco de dos fases

Country Status (9)

Country Link
US (1) US9314441B2 (enExample)
EP (1) EP2768488A4 (enExample)
JP (1) JP2014530855A (enExample)
CN (1) CN103957894A (enExample)
AR (1) AR088369A1 (enExample)
AU (1) AU2012326513B2 (enExample)
BR (1) BR112014009547A8 (enExample)
CA (1) CA2852447A1 (enExample)
WO (1) WO2013058996A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220409351A1 (en) * 2019-11-22 2022-12-29 Emanate Biomedical, Inc. Oral appliance for delivery of an antimicrobial composition

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3419657A (en) 1964-06-23 1968-12-31 Dagra Nv Iodopanoic acid in a hydrogel
US4837255A (en) 1987-03-10 1989-06-06 Ciba-Geigy Corporation Palatable hypocholesterolaemic gel formulation containing a pharmaceutically acceptable non-digestible anion exchange resin
US5030454A (en) * 1987-10-26 1991-07-09 Alza Corporation Method for delivering drug in tiny pills in liquid carrier
JPH04149716A (ja) * 1990-10-15 1992-05-22 Fujitsu Ltd 情報処理装置
RU2113220C1 (ru) * 1991-07-24 1998-06-20 Энзакор Пропертиз Лимитед Композиция, способ лечения кишечной инфекции, способ неспецифической стимуляции имvунной системы, способ доставки биологически активного материала в верхние отделы тонкого кишечника
US5364634A (en) * 1991-11-08 1994-11-15 Southwest Research Institute Controlled-release PH sensitive capsule and adhesive system and method
IL108366A (en) 1993-03-11 1999-11-30 Taro Vit Ind Ltd Semi-solid pharmaceutical compounds and a device for their use
SE9301489D0 (sv) * 1993-04-30 1993-04-30 Ab Astra Veterinary composition
IT1273742B (it) * 1994-08-01 1997-07-09 Lifegroup Spa Composizioni ad elevata bioadesivita' e mucoadesivita' utili per il trattamento di epitali e mucose
DE19529862A1 (de) 1995-08-14 1997-02-20 Rhone Poulenc Rorer Gmbh Pharmazeutische, oral anwendbare Zubereitung
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6071523A (en) 1998-06-03 2000-06-06 Taro Pharmaceuticals Industries, Ltd. Spill resistant pharmaceutical compositions in semi-solid form
CA2243619A1 (fr) 1998-07-17 2000-01-17 Universite De Sherbrooke Hydrogels polyioniques a base de xanthane et chitosane pour stabilisation et relargage controle des vitamines
WO2001015750A1 (en) * 1999-08-27 2001-03-08 Department Of National Defence Hydrogel wound dressing containing liposome-encapsulated therapeutic agent
DE10224086A1 (de) 2002-05-31 2003-12-11 Bayer Ag Pharmazeutische Zubereitungen zur oralen Anwendung enthaltend wirkstoffbeladene Ionentauscherharze sowie strukturviskose Gelbildner als Verdicker
CA2490142A1 (en) * 2002-07-03 2004-01-15 Abbott Laboratories Liquid dosage forms of proton pump inhibitors
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US20040265359A1 (en) 2003-04-17 2004-12-30 Sacks Gordon S. Oral delivery formulations of L-glutamine
US20080226705A1 (en) 2004-03-31 2008-09-18 Soltero Richard A Gel delivery system for oral administration of medicaments
JP5154924B2 (ja) * 2004-05-11 2013-02-27 エガレット エイ／エス ジェランガムを含む膨張可能な投与形態
US9492400B2 (en) * 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
JP4987261B2 (ja) 2005-07-13 2012-07-25 株式会社 メドレックス ゲル状経口製剤
DOP2006000274A (es) 2005-12-14 2007-10-15 Sanofi Aventis Us Llc Formulación de suspensión de fexofenadina
JP2007252341A (ja) * 2006-03-24 2007-10-04 Well Haamonii:Kk 粉末嚥下補助食品
JP2008125435A (ja) * 2006-11-21 2008-06-05 Well Haamonii:Kk ゲル形成性組成物及びこの組成物を含有するゲル
US20080171110A1 (en) * 2007-01-17 2008-07-17 Geoffrey Catherwood Stuart Solids package
JP2009007262A (ja) * 2007-06-26 2009-01-15 Toyo Capsule Kk ビスホスホネート製剤
JP5320091B2 (ja) * 2009-02-02 2013-10-23 大蔵製薬株式会社 医薬成分が長期安定化された経口投与医薬ゼリー製剤
BR112013031209B1 (pt) * 2011-06-07 2020-11-24 Gelesis Llc Metodo para produzir hidrogeis

Also Published As

Publication number Publication date
US20130098797A1 (en) 2013-04-25
AU2012326513B2 (en) 2016-03-17
CN103957894A (zh) 2014-07-30
EP2768488A1 (en) 2014-08-27
EP2768488A4 (en) 2015-04-15
BR112014009547A8 (pt) 2018-01-23
BR112014009547A2 (pt) 2017-04-18
WO2013058996A1 (en) 2013-04-25
JP2014530855A (ja) 2014-11-20
AU2012326513A1 (en) 2014-05-01
US9314441B2 (en) 2016-04-19
CA2852447A1 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
MX2015012559A (es) Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson.
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
AR096439A1 (es) Forma de dosificación resistente al uso indebido que contiene una o más partículas
FI3435996T3 (fi) Elafibranori käytettäväksi primaarisen biliaarisen kolangiitin hoidossa
MX2022013590A (es) Metodos y composiciones para el tratamiento de trastorno por deficit de atencion.
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112015026549A2 (pt) forma de dosagem à prova de violação contendo uma ou mais partículas
BR112012018695A2 (pt) compostos pirazol como antagonistas crth2
JP2014218522A5 (enExample)
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
BR112017008993A2 (pt) métodos e composições especificamente para o tratamento de transtorno de déficit de atenção
BR112015024271A2 (pt) sistema de fornecimento transdérmico
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata
BR112013027486A2 (pt) combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor
HRP20240166T1 (hr) Postupak liječenja prader-willijevog sindroma
BR112014009242A2 (pt) nanossuspensão farmacêutica
BR112015025058A2 (pt) composição farmacêutica capaz de controlar facilmente o padrão de dissolução de lacosamida ou de um sal farmaceuticamente aceitável da mesma
CL2009000330A1 (es) Composicion farmaceutica que comprende microcapsulas de sabor enmascarado con un nucleo de ranitidina y al menos dos recubrimientos sobre el; tabla de rapida desintegracion oral; metodo para preparar la composicion farmaceutica; metodo para preparar la tableta, util para tratar o prevenir trastornos gastrointestinales.
AR088369A1 (es) Sistema de administracion de farmaco de dos fases
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
EP2875823A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CHRONIC OBSTRUCTIVE LUNG DISEASE WITH A PHYLLOSTACHYSIS NIGRA MUNOVAR HENOSIS STAPF PLANT EXTRACT AS AN ACTIVE SUBSTANCE
MX373378B (es) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos.
BR112017022855A2 (pt) combinação de dose fixa inviolável que provê liberação rápida de dois fármacos a partir de partículas e um pó

Legal Events

Date Code Title Description
FB Suspension of granting procedure